Royce Johnson, MD

Kern Medical Center

Disclosure(s): CDC: Travel; F2G: Advisor/Consultant; NIH: Grant/Research Support

Poster(s):

• (P-1187) Olorofim for the treatment of Central Nervous System (CNS) invasive fungal infections (IFI) in patients with limited or no treatment options: a sub-analysis of an open-label, single-arm, Phase 2b trial (Study 32; NCT03583164)
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET